Experimental immune cell therapy tested for aggressive lymphomas
NCT ID NCT07453446
Summary
This early-stage study is testing an experimental treatment called CD30-targeted CAR-T cell therapy for people with lymphoma that has returned or not responded to standard treatments. Researchers will collect immune cells from participants, genetically modify them to better attack cancer, and infuse them back to see if they're safe and can shrink tumors. The study is enrolling adults with specific types of lymphoma that have a marker called CD30, particularly Hodgkin lymphoma and anaplastic large cell lymphoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei Yanda Lu Daopei Hospital
RECRUITINGSanhe, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.